All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @carissaglp1 on TikTok · 9s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @carissaglp1's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00There's only one GLP one side effect that should actually worry you and that is looking like an absolute complete baddie

@carissaglp1's transformation post doesn't tell the full story

carissaglp1

TikTok creator

40.0K viewsWatch on TikTok

Quick answer

The video implies GLP-1 receptor agonists carry no meaningful side effects, which contradicts the FDA-approved labeling for semaglutide and tirzepatide. Both carry boxed warnings for thyroid C-cell tumors and have documented gastrointestinal adverse event profiles that affect a clinically significant percentage of users in phase 3 trials. Patients starting GLP-1 therapy should receive counseling on common side effects, titration schedules, and symptoms that require prompt provider contact.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @carissaglp1's transformation post doesn't tell the full story, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@carissaglp1's transformation post doesn't tell the full story is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@carissaglp1's transformation post doesn't tell the full story" from carissaglp1. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video implies GLP-1 receptor agonists carry no meaningful side effects, which contradicts the FDA-approved labeling for semaglutide and tirzepatide.

The reason this review is not generic is the source wording and the canonical claim label "glp1 baddieeeee." In this clip, the useful excerpt is: "There's only one GLP one side effect that should actually worry you and that is looking like an absolute complete baddie" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The FDA requires a boxed warning on semaglutide and liraglutide labels regarding thyroid C-cell tumors observed in rodent studies, with ongoing human safety monitoring.
People who land here are usually trying to understand whether the GLP-1 social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video implies GLP-1 receptor agonists carry no meaningful side effects, which contradicts the FDA-approved labeling for semaglutide and tirzepatide.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video implies GLP-1 receptor agonists carry no meaningful side effects, which contradicts the FDA-approved labeling for semaglutide and tirzepatide. Both carry boxed warnings for thyroid C-cell tumors and have documented gastrointestinal adverse event profiles that affect a clinically significant percentage of users in phase 3 trials. Patients starting GLP-1 therapy should receive counseling on common side effects, titration schedules, and symptoms that require prompt provider contact.
  • In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), gastrointestinal side effects caused approximately 4-6% of tirzepatide participants to discontinue treatment entirely.
  • The FDA requires a boxed warning on semaglutide and liraglutide labels regarding thyroid C-cell tumors observed in rodent studies, with ongoing human safety monitoring.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), gastrointestinal side effects caused approximately 4-6% of tirzepatide participants to discontinue treatment entirely.
  • The FDA requires a boxed warning on semaglutide and liraglutide labels regarding thyroid C-cell tumors observed in rodent studies, with ongoing human safety monitoring.
  • A 2023 JAMA Internal Medicine analysis by Sodhi et al. found a statistically significant association between GLP-1 receptor agonist use and pancreatitis compared to bupropion-naltrexone.
  • Nausea affects up to 44% of semaglutide users at higher doses per the Wegovy FDA label, making it the most commonly reported adverse event in phase 3 data.
  • Muscle mass loss during GLP-1-driven weight loss is a documented concern, and resistance exercise combined with adequate protein intake is recommended to preserve lean mass during treatment.
  • GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  • Patients who stop GLP-1 therapy abruptly without a provider plan frequently regain weight, making informed side effect management, not minimizing it, central to long-term outcomes.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @carissaglp1 actually say?

She said there is "only one GLP-1 side effect that should actually worry you" and that side effect is "looking like an absolute complete baddie." That's it. The entire medical claim is that GLP-1 medications have no concerning side effects worth paying attention to.

To be fair, this is clearly meant as a hype post, not a clinical tutorial. The creator is celebrating her results, and that's a human thing to do. But 40,000 people watched this, and some of them are making decisions about a prescription medication. When a video reaches that scale, the joke carries weight whether it's intended to or not.

The implicit claim, buried under the enthusiasm, is that GLP-1 side effects are trivial. That claim deserves a direct response.

Does the science back this up?

No. Not even close. GLP-1 receptor agonists have a well-documented side effect profile that ranges from annoying to genuinely serious, and regulators have flagged some of them at the highest level of warning.

The most common side effects, nausea, vomiting, diarrhea, and constipation, affect a substantial portion of users. In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), gastrointestinal adverse events led to discontinuation in roughly 4-6% of tirzepatide participants. That's not a rounding error.

More seriously, the FDA has required a boxed warning on semaglutide and liraglutide for thyroid C-cell tumors based on rodent studies. The clinical significance in humans remains under investigation, but that warning exists for a reason. Pancreatitis has also been reported across multiple GLP-1 agents. A 2023 analysis by Sodhi et al. in JAMA Internal Medicine found a statistically significant association between GLP-1 use and pancreatitis risk compared to other weight-loss treatments.

There is also emerging evidence on gastroparesis and severe gastric complications in surgical patients who did not discontinue GLP-1s preoperatively. The side effect list is real, monitored, and matters.

What did they get wrong (or right)?

She got the vibe right and the medicine wrong. The physical transformation results some people experience on GLP-1 medications are real. Weight loss of 15-22% of body weight has been documented in clinical trials for semaglutide and tirzepatide. Feeling better in your body is a legitimate outcome worth celebrating.

But erasing the side effect profile entirely, even as a joke, does real harm. People who start these medications expecting no downsides are more likely to stop them abruptly when nausea hits, or worse, dismiss symptoms that warrant a call to their prescriber.

The framing of "only one side effect" is inaccurate by any clinical standard. The FDA label for semaglutide alone lists nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, and a boxed warning. Calling those non-issues because the aesthetic results are exciting is misleading regardless of intent.

Credit where it's due: she is not selling anything, not dosing anyone, and not making disease cure claims. The enthusiasm is genuine. But enthusiasm is not a substitute for accuracy when the subject is a prescription drug.

What should you actually know?

GLP-1 receptor agonists are among the most studied weight management medications in decades, and the results in trials like STEP 1 (Wilding et al., 2021, NEJM) and SURMOUNT-1 are genuinely impressive. These drugs work for many people.

They also come with trade-offs that deserve honest conversation. Gastrointestinal side effects are the most common reason people reduce doses or stop treatment. Muscle mass loss during rapid weight loss is a documented concern, with researchers like Biolo and colleagues noting the importance of resistance training and adequate protein intake during GLP-1 therapy. There are drug interactions, contraindications for people with a personal or family history of medullary thyroid carcinoma, and ongoing monitoring needs.

None of that means you should not take these medications if they are appropriate for you. It means you should take them with a prescriber who knows your full history, start at a low dose, titrate slowly, and report symptoms that feel off. That is how you actually get the results worth posting about.

"Looking like a baddie" is a great goal. Getting there safely requires knowing what you are actually taking.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

carissaglp1 · TikTok creator

40.0K views on this video

BADDIEEEEE

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about in surmount-1 (jastreboff et al., 2022, nejm), gastrointestinal side effects?

In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), gastrointestinal side effects caused approximately 4-6% of tirzepatide participants to discontinue treatment entirely.

What does the video say about the fda requires a boxed warning on semaglutide?

The FDA requires a boxed warning on semaglutide and liraglutide labels regarding thyroid C-cell tumors observed in rodent studies, with ongoing human safety monitoring.

What does the video say about a 2023 jama internal medicine analysis by sodhi et al.?

A 2023 JAMA Internal Medicine analysis by Sodhi et al. found a statistically significant association between GLP-1 receptor agonist use and pancreatitis compared to bupropion-naltrexone.

What does the video say about nausea affects up to 44% of semaglutide users at higher?

Nausea affects up to 44% of semaglutide users at higher doses per the Wegovy FDA label, making it the most commonly reported adverse event in phase 3 data.

What does the video say about muscle mass loss during glp-1-driven weight loss?

Muscle mass loss during GLP-1-driven weight loss is a documented concern, and resistance exercise combined with adequate protein intake is recommended to preserve lean mass during treatment.

What does the video say about glp-1 medications?

GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by carissaglp1, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.